P2RY12 and acute coronary syndrome: The mechanism by which platelet P2Y12 inhibition mediates its protection remains unclear, but in this communication, we provide further evidence that the protection is dependent upon the presence of blood, and that, unlike other forms of cardioprotection such as ischaemic conditioning [5], we demonstrate for the first time that P2Y12 inhibitors can result in significant attenuation of injury of myocardium of animals with diabetes, an important co-morbidity in the cohort of patients presenting with an acute coronary syndrome.